IM Cannabis Reports C$1.65 Million Quarterly Revenue and C$7.08 Million Net Loss

IM Cannabis reported third-quarter revenue from continuing operations of C$1.65 million, down from C$5.08 million a year earlier, in results announced on November 13. The Nasdaq-listed medical-cannabis company, which serves patients in Israel, recorded a total quarterly net loss of C$7.08 million, compared with C$3.87 million in the corresponding period of 2025. For the nine months ended September 30, revenue from continuing operations was C$8.96 million, compared with C$15.77 million a year earlier. Gross profit for that period fell to C$1.33 million from C$4.87 million. The company reported a total nine-month net loss of C$13.93 million, against C$3.88 million in 2025. All those amounts are in Canadian dollars. The results reflect a September disposal of European-focused interests while retaining the Israeli business. European operations were classified as discontinued, and the company re-presented the prior-year comparisons for continuing operations. The total net-loss figures include discontinued operations. The filing recorded a C$2.7 million gain on the disposal. At September 30, the company reported cash of about C$2.4 million, compared with C$2.7 million at the end of 2025. Total assets were C$13.7 million and liabilities C$16.7 million. After the reporting period, IM Cannabis closed a US$1.2 million convertible-note private placement with an existing institutional investor on November 4, receiving net proceeds of US$1.02 million.